Sanofi Adr (SNY)

Dec 10, 2025

Celiac Disease Clinical Trial Pipeline Gains Momentum: 20+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - GlobeNewswire Inc.

Dec 10, 2025

Dec 10, 2025

JPMorgan Downgrades Sanofi (SNY) to EUR 95 from EUR 105 - Finviz

Dec 10, 2025

Dec 10, 2025

TEVA Files NDA With FDA for Olanzapine LAI for Schizophrenia - Finviz

Dec 10, 2025

Dec 09, 2025

Teva Stock Trading Above 200- & 50-Day SMA for 2 Months: How to Play - Finviz

Dec 09, 2025

Dec 09, 2025

​Sanofi (SNY) Completes the Acquisition of Vicebio - Finviz

Dec 09, 2025

Dec 01, 2025

REGN Gains 21.5% in a Month: Time to Buy, Sell or Hold the Stock? - Finviz

Dec 01, 2025

Nov 28, 2025

Deutsche Bank Maintains a Buy Rating on Sanofi (SNY) - Finviz

Nov 28, 2025

Nov 26, 2025

Kymera Trades Near 52-Week High: Time to Buy, Sell or Hold the Stock? - Finviz

Nov 26, 2025

Nov 25, 2025

SNY & REGN's Dupixent Gets EU Nod for Chronic Spontaneous Urticaria - Finviz

Nov 25, 2025

Nov 25, 2025

Sanofi Faces Surprise HQ Search As French Authorities Expand Tax Probe - Sahm

Nov 25, 2025

Nov 23, 2025

Bloom Energy-Aktie: Vorsicht geboten! - Finanztrends

Nov 23, 2025

Nov 22, 2025

Abbott-Aktie: 21 Milliarden Dollar für neues Wachstum! - Finanztrends

Nov 22, 2025

Nov 21, 2025

Texas AG Sues Sanofi And Bristol-Myers Over Alleged Failures To Warn About Risks Associated With Blood Thinner Drug - Sahm

Nov 21, 2025

Nov 21, 2025

Wasserstoff-Aktien: Bloom Energy kollabiert erneut, Nel ASA gibt nicht auf und Primary Hydrogen meldet Fortschritte! - Finanztrends

Nov 21, 2025

Nov 21, 2025

A Technical View of the Leifras Co Ltd ADR (LFS) - fostersleader.com

Nov 21, 2025

Nov 17, 2025

Eli Lilly Upgraded, Chewy Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace

Nov 17, 2025

Nov 10, 2025

Why Roche Holding Stock Popped Today - Finviz

Nov 10, 2025

Nov 07, 2025

Novavax Q3 Earnings & Revenues Beat Estimates, '25 Sales View Raised - Finviz

Nov 07, 2025

Oct 28, 2025

Regeneron's Q3 Earnings Outperform Expectations With Dupixent Strength Balancing Eylea Weakness - Sahm

Oct 28, 2025

Oct 27, 2025

UPDATE - GlobeNewswire Inc.

Oct 27, 2025

Oct 24, 2025

Sanofi ADR earnings beat by $0.72, revenue fell short of estimates - Investing.com Nigeria

Oct 24, 2025

Oct 24, 2025

Dupixent Pushes Sanofi's Quarterly Sales Past $14.5 Billion Mark - Sahm

Oct 24, 2025

Oct 22, 2025

Sanofi Drug Shows Superior Efficacy In Genetic Disease Compared To Current Standard Therapy - Sahm

Oct 22, 2025

Oct 17, 2025

Sanofi's Rezurock Approval Stumbles In EU For Chronic Graft-Vs-Host Disease - Sahm

Oct 17, 2025

Oct 17, 2025

FDA Unveils First Experimental Drugs Under Fast-Track Voucher Plan To Cut Drug Review Times - Sahm

Oct 17, 2025

Oct 16, 2025

Sanofi’s AlphaMedix Achieves Key Efficacy Endpoints in Phase 2 Study - The Globe and Mail

Oct 16, 2025

Oct 16, 2025

Sanofi (SNYNF) Gets a Buy from J.P. Morgan - The Globe and Mail

Oct 16, 2025

Oct 14, 2025

Hedge Fund Shah Capital Urges Novavax To Consider Sale Amid Vaccine Rollout Struggles, Sees $5 Billion Potential - Sahm

Oct 14, 2025